Joseph J. Vadakara
Expertise in
45
conditions

Dr. Joseph J. Vadakara

Hematology | Oncology
100 North Academy Avenue, 
Danville, PA 
Accepting New Patients
Referral may be required
Before you request
Expertise in
45
conditions
100 North Academy Avenue, 
Danville, PA 

Overview

Dr. Vadakara is a board-certified and fellowship-trained cancer physician specializing in bone marrow transplantation. Dr. Vadakara obtained his medical degree from Medical College Thiruvananthapuram. He completed his residency at Hahnemann University Hospital and his fellowship in hematology and oncology at Fox Chase Cancer Center. Dr. Vadakara is certified by the American Board of Internal Medicine in hematology and medical oncology.

Dr. Vadakara is highly rated in 45 conditions, according to our data. His clinical expertise encompasses Thrombocytopenia, Adult Immune Thrombocytopenia, Hemangioma Thrombocytopenia Syndrome, Bone Marrow Aspiration, and Bone Marrow Transplant.

Dr. Vadakara is board certified in The American Board Of Internal Medicine In Hematology And Medical Oncology. He is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 30 clinical trials. Dr. Vadakara is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in PA

Board Certifications

The American Board Of Internal Medicine In Hematology And Medical Oncology

Fellowships

Fox Chase Cancer Center, 2013

Hospital Affiliations

Geisinger Wyoming Valley Medical Center
Geisinger Medical Center
Geisinger-Bloomsburg Hospital
Wellspan Evangelical Community Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Moda Health
  • EPO
  • PPO
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Geisinger Medical Center - Hematology and Oncology
100 North Academy Avenue, Danville, PA 17822

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

30 Clinical Trials

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 2
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL)
A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL)
Enrollment Status: Active_not_recruiting
Publish Date: August 06, 2026
Intervention Type: Other
Study Phase: Not Applicable
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
View 9 Less Clinical Trials

2 Total Publications

Genetic Landscape of Myelodysplastic Syndrome and Clonal Hematopoiesis: Insights From Whole Exome Sequencing of 90 000 Individuals.
Genetic Landscape of Myelodysplastic Syndrome and Clonal Hematopoiesis: Insights From Whole Exome Sequencing of 90 000 Individuals.
Journal: American journal of hematology
Published: January 25, 2025
Similar Doctors
Expertise in
7
conditions
Dr. Jonathan A. Bernstein
Hematology | Oncology
Expertise in
7
conditions
Dr. Jonathan A. Bernstein
Hematology | Oncology
Referral may be required

The Milton S. Hershey Medical Center

500 University Dr, 
Hershey, PA 
 (48.8 miles away)
800-243-1455
Languages Spoken:
English
See accepted insurances

Jonathan Bernstein is a Hematologist and an Oncologist practicing medicine in Hershey, Pennsylvania. Dr. Bernstein is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Chronic Spontaneous Urticaria (CSU), Hemophilia A, Mast Cell Activation Syndrome (MCAS), and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP).

Expertise in
22
conditions
Dr. Nelson S. Yee
Hematology | Oncology
Expertise in
22
conditions
Dr. Nelson S. Yee
Hematology | Oncology
Referral may be required

The Milton S. Hershey Medical Center

500 University Dr, 
Hershey, PA 
 (48.8 miles away)
800-243-1455
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nelson Yee is a Hematologist and an Oncologist practicing medicine in Hershey, Pennsylvania. Dr. Yee is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Neuroendocrine Tumor, Familial Pancreatic Cancer, and Bone Marrow Aspiration.

Expertise in
25
conditions
Dr. Seema G. Naik
Hematology | Oncology
Expertise in
25
conditions
Dr. Seema G. Naik
Hematology | Oncology
Referral may be required

The Milton S. Hershey Medical Center

500 University Dr, 
Hershey, PA 
 (48.8 miles away)
717-531-8401
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Seema Naik is a Hematologist and an Oncologist practicing medicine in Hershey, Pennsylvania. Dr. Naik is highly rated in 25 conditions, according to our data. Her clinical expertise encompasses Burkitt Lymphoma, B-Cell Lymphoma, Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Joseph J. Vadakara

How do I make an appointment with Dr. Joseph J. Vadakara?

You can book an appointment with Dr. Joseph J. Vadakara by calling their office at 800-275-6401. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Joseph J. Vadakara a top-rated expert for Thrombocytopenia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Joseph J. Vadakara is classified as an Distinguished expert for Thrombocytopenia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Joseph J. Vadakara specialize in?

While Dr. Joseph J. Vadakara is a Hematology, they have specific expertise in Thrombocytopenia, Adult Immune Thrombocytopenia, and Hemangioma Thrombocytopenia Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Joseph J. Vadakara participate in research or clinical trials?

Yes. Dr. Joseph J. Vadakara has published 2 articles and abstracts on conditions like Thrombocytopenia. You can view a list of Dr. Joseph J. Vadakara's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Joseph J. Vadakara accept my insurance?

Dr. Joseph J. Vadakara accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 800-275-6401 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Vadakara's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 36 Advanced Conditions
    View All 115 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile